Class information for: |
Basic class information |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
10 | 4 | IMMUNOLOGY//TRANSPLANTATION//RHEUMATOLOGY | 1369268 |
97 | 3 | EPSTEIN BARR VIRUS//HEMATOLOGY//LYMPHOMA | 77599 |
90 | 2 | CHRONIC LYMPHOCYTIC LEUKEMIA//MANTLE CELL LYMPHOMA//FOLLICULAR LYMPHOMA | 26562 |
2524 | 1 | FOLLICULAR LYMPHOMA//RADIOIMMUNOTHERAPY//RITUXIMAB | 2251 |
Terms with highest relevance score |
rank | Category | termType | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|---|
1 | FOLLICULAR LYMPHOMA | authKW | 2357924 | 20% | 37% | 460 |
2 | RADIOIMMUNOTHERAPY | authKW | 647716 | 11% | 19% | 244 |
3 | RITUXIMAB | authKW | 476139 | 17% | 9% | 387 |
4 | Y 90 IBRITUMOMAB TIUXETAN | authKW | 364862 | 2% | 74% | 35 |
5 | IBRITUMOMAB TIUXETAN | authKW | 298906 | 1% | 65% | 33 |
6 | ZEVALIN | authKW | 287143 | 1% | 71% | 29 |
7 | YTTRIUM 90 IBRITUMOMAB TIUXETAN | authKW | 268421 | 1% | 91% | 21 |
8 | TOSITUMOMAB | authKW | 202143 | 1% | 76% | 19 |
9 | INDOLENT LYMPHOMA | authKW | 197077 | 2% | 40% | 35 |
10 | I 131 TOSITUMOMAB | authKW | 188619 | 1% | 84% | 16 |
Web of Science journal categories |
chi_square_rank | Category | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | Hematology | 40473 | 41% | 0% | 916 |
2 | Oncology | 27192 | 57% | 0% | 1276 |
3 | Transplantation | 3136 | 8% | 0% | 181 |
4 | Radiology, Nuclear Medicine & Medical Imaging | 796 | 8% | 0% | 190 |
5 | Immunology | 499 | 9% | 0% | 199 |
6 | Medicine, General & Internal | 106 | 5% | 0% | 111 |
7 | Medicine, Research & Experimental | 75 | 3% | 0% | 77 |
8 | Pharmacology & Pharmacy | 41 | 5% | 0% | 120 |
9 | Cell & Tissue Engineering | 24 | 0% | 0% | 9 |
10 | Pathology | 12 | 1% | 0% | 31 |
Address terms |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | HLTH SCI NURSING BIOSTAT | 58329 | 0% | 83% | 5 |
2 | GENENTECH BIOONCOL | 41998 | 0% | 100% | 3 |
3 | HEMATOL | 41657 | 18% | 1% | 395 |
4 | LYMPHOMA MYELOMA | 39499 | 2% | 6% | 49 |
5 | AZIENDA OSPED S EUGENIO | 27999 | 0% | 100% | 2 |
6 | BRITISH LYMPHOMA INVEST OFF | 27999 | 0% | 100% | 2 |
7 | CATTEDRA SERV EMATOL | 27999 | 0% | 100% | 2 |
8 | HOSPICES CIVILS LYON HEAD | 27999 | 0% | 100% | 2 |
9 | LYMPHOMA ORG | 27999 | 0% | 100% | 2 |
10 | TULANE CANC HEMATOL ONCOL FELLOWSHIP PROGRAM | 27999 | 0% | 100% | 2 |
Journals |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | LEUKEMIA & LYMPHOMA | 35856 | 6% | 2% | 141 |
2 | CLINICAL LYMPHOMA | 29719 | 1% | 13% | 17 |
3 | JOURNAL OF CLINICAL ONCOLOGY | 27460 | 8% | 1% | 180 |
4 | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 21963 | 3% | 2% | 71 |
5 | ANNALS OF ONCOLOGY | 21005 | 5% | 1% | 113 |
6 | BONE MARROW TRANSPLANTATION | 15309 | 4% | 1% | 99 |
7 | SEMINARS IN ONCOLOGY | 11262 | 3% | 1% | 65 |
8 | CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 11202 | 1% | 3% | 26 |
9 | CLINICAL LYMPHOMA & MYELOMA | 9723 | 1% | 5% | 15 |
10 | HEMATOLOGICAL ONCOLOGY | 8883 | 1% | 3% | 24 |
Author Key Words |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass | LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | FOLLICULAR LYMPHOMA | 2357924 | 20% | 37% | 460 | Search FOLLICULAR+LYMPHOMA | Search FOLLICULAR+LYMPHOMA |
2 | RADIOIMMUNOTHERAPY | 647716 | 11% | 19% | 244 | Search RADIOIMMUNOTHERAPY | Search RADIOIMMUNOTHERAPY |
3 | RITUXIMAB | 476139 | 17% | 9% | 387 | Search RITUXIMAB | Search RITUXIMAB |
4 | Y 90 IBRITUMOMAB TIUXETAN | 364862 | 2% | 74% | 35 | Search Y+90+IBRITUMOMAB+TIUXETAN | Search Y+90+IBRITUMOMAB+TIUXETAN |
5 | IBRITUMOMAB TIUXETAN | 298906 | 1% | 65% | 33 | Search IBRITUMOMAB+TIUXETAN | Search IBRITUMOMAB+TIUXETAN |
6 | ZEVALIN | 287143 | 1% | 71% | 29 | Search ZEVALIN | Search ZEVALIN |
7 | YTTRIUM 90 IBRITUMOMAB TIUXETAN | 268421 | 1% | 91% | 21 | Search YTTRIUM+90+IBRITUMOMAB+TIUXETAN | Search YTTRIUM+90+IBRITUMOMAB+TIUXETAN |
8 | TOSITUMOMAB | 202143 | 1% | 76% | 19 | Search TOSITUMOMAB | Search TOSITUMOMAB |
9 | INDOLENT LYMPHOMA | 197077 | 2% | 40% | 35 | Search INDOLENT+LYMPHOMA | Search INDOLENT+LYMPHOMA |
10 | I 131 TOSITUMOMAB | 188619 | 1% | 84% | 16 | Search I+131+TOSITUMOMAB | Search I+131+TOSITUMOMAB |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Classes with closest relation at Level 1 |